FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 609 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR pCR Associated with Improved Survival Outcomes in Patients with Soft Tissue... April 3, 2023 Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced... August 9, 2022 Selpercatinib Shows Durable Efficacy in RET Fusion–positive NSCLC August 27, 2020 Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer May 7, 2021 Load more HOT NEWS ASCO20 Virtual Research Round Up Podcast: Leukemia, Colorectal Cancer, and Lung... New Cancer Diagnoses Jump at Age 65, Suggesting People Put Off... Five Questions With…Stephen. Snowboarder Wins Gold Medal At Winter Olympics After Beating Cancer
